ES2103408T3 - Analogos de oligorribonucleotidos y ribozimas con uniones terminales en 3'-3' o 5'-5' respectivamente. - Google Patents

Analogos de oligorribonucleotidos y ribozimas con uniones terminales en 3'-3' o 5'-5' respectivamente.

Info

Publication number
ES2103408T3
ES2103408T3 ES93114773T ES93114773T ES2103408T3 ES 2103408 T3 ES2103408 T3 ES 2103408T3 ES 93114773 T ES93114773 T ES 93114773T ES 93114773 T ES93114773 T ES 93114773T ES 2103408 T3 ES2103408 T3 ES 2103408T3
Authority
ES
Spain
Prior art keywords
ribozymes
oligorribonucleotides
analogs
terminal joints
terminal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93114773T
Other languages
English (en)
Inventor
H Prof Dr Seliger
Flavio Ramalho Dr Ortigao
Hannelore Rosch
Rudi Rosch
Bernd Krist
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Original Assignee
Hoechst AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6468696&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2103408(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoechst AG filed Critical Hoechst AG
Application granted granted Critical
Publication of ES2103408T3 publication Critical patent/ES2103408T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Shaping Of Tube Ends By Bending Or Straightening (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

LA INVENCION SE REFIERE A LA ANALOGIA DE OLIGORRIBONUCLEOTIDOS ANALOGOS CON LIGADURAS 3''-3'' TERMINALES. ESTA MODIFICACION ESTABILIZA LAS MOLECULAS ASI MODIFICADA, INCLUIDA TAMBIEN LA RIBOZIMA, SIN QUE SUS PROPIEDADES CAMBIEN DE FORMA DESVENTAJOSA, INCLUIDO TAMBIEN EVENTUALMENTE ACTIVIDADES CATALITICAS.
ES93114773T 1992-09-24 1993-09-14 Analogos de oligorribonucleotidos y ribozimas con uniones terminales en 3'-3' o 5'-5' respectivamente. Expired - Lifetime ES2103408T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4231949 1992-09-24

Publications (1)

Publication Number Publication Date
ES2103408T3 true ES2103408T3 (es) 1997-09-16

Family

ID=6468696

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93114773T Expired - Lifetime ES2103408T3 (es) 1992-09-24 1993-09-14 Analogos de oligorribonucleotidos y ribozimas con uniones terminales en 3'-3' o 5'-5' respectivamente.

Country Status (14)

Country Link
US (1) US6420546B1 (es)
EP (1) EP0593901B2 (es)
JP (1) JP3653102B2 (es)
AT (1) ATE151773T1 (es)
AU (1) AU665113B2 (es)
CA (1) CA2106819C (es)
DE (1) DE59306170D1 (es)
DK (1) DK0593901T3 (es)
ES (1) ES2103408T3 (es)
FI (1) FI115400B (es)
GR (1) GR3023858T3 (es)
HU (1) HU219638B (es)
NO (1) NO307656B1 (es)
NZ (1) NZ248739A (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5646042A (en) * 1992-08-26 1997-07-08 Ribozyme Pharmaceuticals, Inc. C-myb targeted ribozymes
US5998203A (en) * 1996-04-16 1999-12-07 Ribozyme Pharmaceuticals, Inc. Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
ES2221942T3 (es) * 1996-05-24 2005-01-16 Aventis Pharma Deutschland Gmbh Reactivo y metodo para inhibir la expresion de n-ras.
US7572582B2 (en) 1997-09-12 2009-08-11 Exiqon A/S Oligonucleotide analogues
WO1999054459A2 (en) * 1998-04-20 1999-10-28 Ribozyme Pharmaceuticals, Inc. Nucleic acid molecules with novel chemical compositions capable of modulating gene expression
DE19935303A1 (de) 1999-07-28 2001-02-08 Aventis Pharma Gmbh Oligonukleotide zur Inhibierung der Expression von humanem eg5
EP2322648A1 (en) 2000-09-26 2011-05-18 Duke University RNA aptamers and methods for identifying the same
US7300922B2 (en) 2001-05-25 2007-11-27 Duke University Modulators of pharmacological agents
KR101147147B1 (ko) 2004-04-01 2012-05-25 머크 샤프 앤드 돔 코포레이션 Ｒｎａ 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
PT1745062E (pt) 2004-04-22 2014-07-11 Regado Biosciences Inc Moduladores melhorados de fatores de coagulação
US20060166234A1 (en) 2004-11-22 2006-07-27 Barbara Robertson Apparatus and system having dry control gene silencing compositions
US7923207B2 (en) 2004-11-22 2011-04-12 Dharmacon, Inc. Apparatus and system having dry gene silencing pools
US7935811B2 (en) 2004-11-22 2011-05-03 Dharmacon, Inc. Apparatus and system having dry gene silencing compositions
EP1820804A1 (en) * 2006-02-20 2007-08-22 Humboldt-Universität zu Berlin Lipidated oligonucleotides
EP2081949B1 (en) 2006-09-22 2014-12-10 GE Healthcare Dharmacon, Inc. Tripartite oligonucleotide complexes and methods for gene silencing by rna interference
US7845686B2 (en) * 2007-12-17 2010-12-07 S & B Technical Products, Inc. Restrained pipe joining system for plastic pipe
US8188060B2 (en) 2008-02-11 2012-05-29 Dharmacon, Inc. Duplex oligonucleotides with enhanced functionality in gene regulation
EP2781523A1 (en) 2013-03-18 2014-09-24 Miltenyi Biotec GmbH Lipophilic oligonucleotide analogs
EP3500581A4 (en) 2016-08-17 2021-10-06 Solstice Biologics, Ltd. POLYNUCLEOTIDE CONSTRUCTS
US11597744B2 (en) 2017-06-30 2023-03-07 Sirius Therapeutics, Inc. Chiral phosphoramidite auxiliaries and methods of their use
US11104941B2 (en) 2018-09-28 2021-08-31 Bioo Scientific Corporation 5′ adapter comprising an internal 5′-5′ linkage
CN118373865A (zh) * 2024-06-25 2024-07-23 苏州诺维康生物科技有限公司 一种4-乙酰氨基-1-(2-脱氧-2-氟-beta-D-阿拉伯呋喃基)-2(1H)-嘧啶酮的新合成方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3916871A1 (de) 1989-05-24 1990-11-29 Boehringer Mannheim Gmbh Modifiziertes phosphoramidit-verfahren zur herstellung von modifizierten nukleinsaeuren
US5399676A (en) * 1989-10-23 1995-03-21 Gilead Sciences Oligonucleotides with inverted polarity
EP0464638B1 (de) * 1990-07-02 1997-04-02 Hoechst Aktiengesellschaft Oligonucleotid-analoge mit terminalen 3'-3'-bzw. 5'-5'-Internucleotidverknüpfungen
US5672697A (en) * 1991-02-08 1997-09-30 Gilead Sciences, Inc. Nucleoside 5'-methylene phosphonates
FI115214B (fi) * 1992-01-22 2005-03-31 Hoechst Ag Menetelmä oligonukleotidianalogien valmistamiseksi ja niiden käyttö
US5646261A (en) * 1992-01-22 1997-07-08 Hoechst Aktiengesellschaft 3'-derivatized oligonucleotide analogs with non-nucleotidic groupings, their preparation and use

Also Published As

Publication number Publication date
EP0593901B2 (de) 2008-04-09
CA2106819C (en) 2007-04-17
HU9302697D0 (en) 1993-12-28
ATE151773T1 (de) 1997-05-15
EP0593901A2 (de) 1994-04-27
FI934154A0 (fi) 1993-09-22
EP0593901A3 (en) 1994-09-28
DE59306170D1 (de) 1997-05-22
DK0593901T3 (da) 1997-10-27
GR3023858T3 (en) 1997-09-30
JP3653102B2 (ja) 2005-05-25
NO933397D0 (no) 1993-09-23
NO933397L (no) 1994-03-25
HU219638B (hu) 2001-06-28
FI934154A (fi) 1994-03-25
EP0593901B1 (de) 1997-04-16
CA2106819A1 (en) 1994-03-25
US6420546B1 (en) 2002-07-16
NO307656B1 (no) 2000-05-08
AU4755193A (en) 1994-03-31
FI115400B (fi) 2005-04-29
NZ248739A (en) 1995-08-28
HUT66458A (en) 1994-11-28
JPH06189753A (ja) 1994-07-12
AU665113B2 (en) 1995-12-14

Similar Documents

Publication Publication Date Title
ES2103408T3 (es) Analogos de oligorribonucleotidos y ribozimas con uniones terminales en 3'-3' o 5'-5' respectivamente.
DE69021263D1 (de) Fibronektinbindungsprotein und dessen Herstellung.
DE3887625D1 (de) Verfahren zur Herstellung von 1,1,1-Trifluorodichlorethan und von 1,1,1,2-Tetrafluorchlorethan.
DE69325970D1 (de) Walzdraht, Feinstdraht und verdrillter Draht aus Stahl, Verfahren zur Herstellung von Feinstdraht
ATA163595A (de) Hochmolekulare und niedermolekulare fraktionen des von willebrand-faktors
DE69030543D1 (de) Chitin-Oligomer mit endständiger 2,5-Anhydromannitolgruppe und Verfahren zur Herstellung von Chitin- oder Chitosan-Oligomeren
ATE312174T1 (de) Antisense-oligonucleotide gegen hsv-1 sowie deren herstellung
ATE120494T1 (de) Fibronectinbindungsprotein und dessen herstellung.
DE59101172D1 (de) Verfahren zur Herstellung von oxidationsstabilen und kältestabilen Grundölen und Mitteldestillaten.
DE69400342D1 (de) Verfahren zur Herstellung von 1,1,1,2-Tetrafluor-2-Chlorethan und Pentafluorethan
DE59305227D1 (de) Verfahren zur Herstellung von 2-Methyl-1,4-butandiol und 3-Methyltetrahydrofuran
DE69428084D1 (de) Verfahren zur Herstellung von porösen Geweben für Aufgussbeutel, und hergestellte Gewebe
DE69313832D1 (de) Verfahren zur Herstellung von 2,4-Dihydroxydiphenylsulfon
ATE308617T1 (de) Rantes mutanten und deren therapeutischen anwendungen
MX22991A (es) Agente edulcorante derivado del acido l-aspartico o l-glutamico y el procedimiento para su preparacion.
DE69205535D1 (de) Verfahren zur Herstellung von Phenylbutyronitrilen und Verwendung in der Parfümerie des 2,2-Dimethyl-4-Phenyl-Valeriannitrile.
DE59301021D1 (de) Verfahren zur kontinuierlichen Herstellung von 3-Cyano-3,5,5-trimethylcyclohexanon.
DE59401800D1 (de) Verfahren zur Herstellung von 1,1'-Binaphthylen
DE68922507D1 (de) Verfahren zur Herstellung von beta-2',2'-Difluornukleosiden.
DE69435058D1 (de) Vektor zur vielfachklonierung, expressionsvektor und herstellung von fremdprotein mit expressionsvektor
DE69326050D1 (de) Verfahren zur Herstellung von 0,0'-Diacylweinsäureanhydrid und Verfahren zur Herstellung von 0,0'-Diacylweinsäure
DE59404420D1 (de) Verbessertes Verfahren zur Herstellung von 2,2'-Dinitrodiphenyldisulfid
DE59103040D1 (de) Verfahren zur Herstellung von symmetrischen 2,2'-Methylen-bis-benztriazolylphenolen.
RU93054766A (ru) Олигорибонуклеотиды и их рибозимные аналоги с концевыми 3'-3'-соответственно, 5'-5'-связями
DE59300999D1 (de) Verfahren zur Herstellung von N-Hydroxy-N'-diazeniumoxiden.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 593901

Country of ref document: ES